{"entity":{"type":"insider","cik":"0001844435","url":"/insider/0001844435","json_url":"/insider/0001844435.json","name":"5AM Ventures VII, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":22,"n_filings":6,"first":"2024-02-02","last":"2026-08-20","span_basis":"filed_date"},"name_variants":[{"name":"5AM Ventures VII, L.P.","source":"filing","n_filings":6,"first_seen":"2024-02-02","last_seen":"2026-08-20"}],"transactions":[{"id":9299370,"accession":"0001231919-26-000959","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7700.0,"shares_display":"7,700","price_per_share":0.32,"price_display":"0.32","price_state":"stated","total_value":2464.0,"total_display":"2,464.00","total_whole":"2,464","shares_owned_after":7850155.0,"shares_owned_after_display":"7,850,155","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-20","filed_date":"2026-08-20","scope":"insider","n_lines":3},{"id":9299367,"accession":"0001231919-26-000959","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":68140.0,"shares_display":"68,140","price_per_share":0.35,"price_display":"0.35","price_state":"stated","total_value":23849.0,"total_display":"23,849.00","total_whole":"23,849","shares_owned_after":7856650.0,"shares_owned_after_display":"7,856,650","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-19","filed_date":"2026-08-20","scope":"insider","n_lines":3},{"id":9299364,"accession":"0001231919-26-000959","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-26-000959","line_url":"/filing/0001231919-26-000959","is_derivative":false,"issuer_cik":"0001516551","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001516551","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300000.0,"shares_display":"300,000","price_per_share":0.38,"price_display":"0.38","price_state":"stated","total_value":114000.0,"total_display":"114,000.00","total_whole":"114,000","shares_owned_after":7914126.0,"shares_owned_after_display":"7,914,126","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-18","filed_date":"2026-08-20","scope":"insider","n_lines":3},{"id":5150256,"accession":"0001231919-25-000196","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000196","line_url":"/filing/0001231919-25-000196#line-1","is_derivative":false,"issuer_cik":"0001664281","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001664281","owner_cik":null,"owner_name":"5AM Ventures VII, L.P.; 5AM Opportunities II, L.P.; PARMAR KUSH; 5AM Opportunities II (GP), LLC; 5AM Ventures VI, L.P.; 5AM Partners VII, LLC","owner_display_name":"5AM Ventures VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2941176.0,"shares_display":"2,941,176","price_per_share":1.53,"price_display":"1.53","price_state":"stated","total_value":4499999.28,"total_display":"4,499,999.28","total_whole":"4,499,999","shares_owned_after":2941176.0,"shares_owned_after_display":"2,941,176","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-11","filed_date":"2025-09-15","scope":"insider"},{"id":5040315,"accession":"0001415889-25-022806","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-022806","line_url":"/filing/0001415889-25-022806","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Ventures II LP; PARMAR KUSH; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":170449.0,"shares_display":"170,449","price_per_share":3.42,"price_display":"3.42","price_state":"stated","total_value":582935.58,"total_display":"582,935.58","total_whole":"582,936","shares_owned_after":1457064.0,"shares_owned_after_display":"1,457,064","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-22","filed_date":"2025-08-22","scope":"insider","n_lines":2},{"id":5040307,"accession":"0001415889-25-022806","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-022806","line_url":"/filing/0001415889-25-022806","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Ventures II LP; PARMAR KUSH; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; ROCKLAGE SCOTT M","owner_display_name":"5AM CO-INVESTORS II LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60956.0,"shares_display":"60,956","price_per_share":3.57,"price_display":"3.57","price_state":"stated","total_value":217612.92,"total_display":"217,612.92","total_whole":"217,613","shares_owned_after":1621043.0,"shares_owned_after_display":"1,621,043","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-21","filed_date":"2025-08-22","scope":"insider","n_lines":2},{"id":2756628,"accession":"0001415889-24-023399","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-023399","line_url":"/filing/0001415889-24-023399","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M; 5AM CO-INVESTORS II LP","owner_display_name":"5AM Ventures VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13837.0,"shares_display":"13,837","price_per_share":6.06,"price_display":"6.06","price_state":"stated","total_value":83852.22,"total_display":"83,852.22","total_whole":"83,852","shares_owned_after":8167206.0,"shares_owned_after_display":"8,167,206","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-13","filed_date":"2024-09-13","scope":"insider","n_lines":3},{"id":2756602,"accession":"0001415889-24-023399","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-023399","line_url":"/filing/0001415889-24-023399","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M; 5AM CO-INVESTORS II LP","owner_display_name":"5AM Ventures VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":252500.0,"shares_display":"252,500","price_per_share":6.6,"price_display":"6.60","price_state":"stated","total_value":1666500.0,"total_display":"1,666,500.00","total_whole":"1,666,500","shares_owned_after":8178964.0,"shares_owned_after_display":"8,178,964","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-11","filed_date":"2024-09-13","scope":"insider","n_lines":3},{"id":3252339,"accession":"0001415889-24-008107","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-008107","line_url":"/filing/0001415889-24-008107#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures VII, L.P.; ROCKLAGE SCOTT M; 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; DIEKMAN JOHN D; PARMAR KUSH; 5AM Ventures II LP","owner_display_name":"5AM Ventures VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":450000.0,"shares_display":"450,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":4500000.0,"total_display":"4,500,000.00","total_whole":"4,500,000","shares_owned_after":8393520.0,"shares_owned_after_display":"8,393,520","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-15","scope":"insider"},{"id":2320409,"accession":"0001209191-24-002643","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-24-002643","line_url":"/filing/0001209191-24-002643#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Skye Bioscience, Inc.","issuer_ticker":"SKYE","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Partners II, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; 5AM Partners VII, LLC; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M","owner_display_name":"5AM Partners II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5206074.0,"shares_display":"5,206,074","price_per_share":2.31,"price_display":"2.31","price_state":"stated","total_value":12026030.94,"total_display":"12,026,030.94","total_whole":"12,026,031","shares_owned_after":7943520.0,"shares_owned_after_display":"7,943,520","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-31","filed_date":"2024-02-02","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001516551","name":"Skye Bioscience, Inc.","url":"/issuer/0001516551","role":"Ten percent owner","n_filings":5,"first_seen":"2024-02-02","last_seen":"2026-08-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001736730","name":"Camp4 Therapeutics Corp","url":"/issuer/0001736730","role":"Ten percent owner","n_filings":1,"first_seen":"2025-09-15","last_seen":"2025-09-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001844435","retrieved_at":"2026-08-24T17:07:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}